Wednesday, July 16, 2014 5:47:56 PM
Yup the very same upstanding gentleman described from this Bio below:
Mr. Nasrat Hakim has been the Chief Executive Officer and President of Elite Pharmaceuticals, Inc. since August 1, 2013. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He has a proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. He served as a Vice President of Quality Compliance and Technical Services at Actavis LLC. Mr. Hakim served as Vice President of Quality of Alexza Pharmaceuticals Inc. since July 18, 2007. Mr. Hakim served as Corporate Vice President of Quality and Compliance for Actavis / Alpharma Inc., and previously served as Global Vice President of Compliance for Alpharma, where he was employed from 2004 to 2007. He has been a Director at Elite Pharmaceuticals, Inc since August 1, 2013. Mr. Hakim has also served as Executive Director of Corporate Compliance and Technical Projects for Watson Pharmaceuticals and Executive Director, Site Head of Quality and Compliance at TheraTech, Inc. Watson Pharmaceuticals acquired TheraTech in 1999. Mr. Hakim holds both a JD and BS in Law from Saratoga University in San Jose, California, a Masters degree (LLM) in Law from St. Thomas University in Miami, Florida and Bachelors and Masters degrees in Chemistry from California State University at Sacramento.
Yup, totally sounds like this sort would resort to such trickery.
I bet if we dig a little deeper we will find all kinds of shenanigans!
Let's see what he has been up to:
• Twenty six years of pharmaceutical and medical industry experience in Quality Assurance, Quality Control, AR&D and Regulatory Compliance.
• Educational discipline in Law (JD/LLM), Business, Regulatory Affairs (RAC) and Chemistry/Bio-Chemistry (MS).
• Proven management experience establishing new departments, building cross-functional teams, creating sustainable GxP-compliant programs and preparing domestic and international sites for successful FDA/regulatory inspections.
• Extensive quality experience designing and implementing Corporate Quality Systems impacting multiple sites, and managing internal and external compliance oversight and risk assessment.
• In-depth technical knowledge of quality and manufacturing systems and technologies including immediate and extended release formulations used in solid dosage, transdermals, (Medical Device) insert and implant finished products.
• Solid regulatory command of GMP’s, national and International regulations. Ability to research, analyze and implement systems to comply with global regulations in support of timely and successful new product applications.
• Successful change agent via creation and implementation of global compliance program and remediation of existing programs and systems across multiple sites.
Ok, but with a terrible track record such as this guys he must have hardly any connection right!?
LOL! 500+ connections
http://www.linkedin.com/pub/nasrat-hakim/6/261/293
Favorite Quote:
"Trust Me .... pleaseeee! I am a long, short, trader, flipper; I am confused. The only thing that I know for sure is that I have one account with 10 shares in it. Whew! Guess that makes me a long?"
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/27/2024 08:30:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 09:16:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:05:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
FEATURED Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM
BNCM COMPLETES MERGER WITH DELEX HEALTHCARE • BNCM • Oct 8, 2024 9:54 AM
CBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024 • CBDL • Oct 8, 2024 8:00 AM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM